| REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis (NCT06955416) | POLYSAN Scientific & Technological Pharmaceutical Company | 2025-05-01 |
| Trial of the Efficacy and Safety of Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old (NCT07066540) | POLYSAN Scientific & Technological Pharmaceutical Company | 2024-08-01 |
| Evaluation of the Efficacy of Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN Tablets, at 2-3 Stages of Rehabilitation of Patients With Post Intensive Care Syndrome (NCT06735898) | POLYSAN Scientific & Technological Pharmaceutical Company | 2024-03-01 |
| Observational Study of Efficiency of Cytoflavin, in Patients With Ischemic Stroke Not Receiving Reperfusion Therapy (NCT06514976) | POLYSAN Scientific & Technological Pharmaceutical Company | 2024-03-01 |
| Study of Safety and Efficacy of the Drug Cycloferone in Patients with Acute Respiratory Viral Infection (NCT06286254) | POLYSAN Scientific & Technological Pharmaceutical Company | 2023-09-20 |
| Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza (NCT06183229) | POLYSAN Scientific & Technological Pharmaceutical Company | 2023-09-15 |
| Cytoflavin in the Complex Rehabilitation of Stroke Patients (NCT05935787) | POLYSAN Scientific & Technological Pharmaceutical Company | 2023-06-30 |
| Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis (NCT06183242) | POLYSAN Scientific & Technological Pharmaceutical Company | 2023-05-27 |
| Remaxol® Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive Jaundice (NCT05928286) | POLYSAN Scientific & Technological Pharmaceutical Company | 2022-12-01 |
| Study of Safety and Efficiency of the Drug Reamberin® in the Intensive Care of Patients With Acute Ethanol Intoxication (NCT05715723) | POLYSAN Scientific & Technological Pharmaceutical Company | 2022-09-15 |
| Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy (NCT05789797) | POLYSAN Scientific & Technological Pharmaceutical Company | 2022-05-12 |
| Cytoflavin in Combination With Reperfusion in Stroke Patients (NCT05297851) | POLYSAN Scientific & Technological Pharmaceutical Company | 2022-04-10 |
| Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill Patients (NCT05147051) | POLYSAN Scientific & Technological Pharmaceutical Company | 2021-06-16 |
| Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19 (NCT05172180) | POLYSAN Scientific & Technological Pharmaceutical Company | 2020-12-01 |
| Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy (NCT04649203) | POLYSAN Scientific & Technological Pharmaceutical Company | 2020-11-25 |
| International Trial of Efficacy of Cytoflavin in Head Trauma (NCT04631484) | POLYSAN Scientific & Technological Pharmaceutical Company | 2020-11-22 |
| "Unifuzol®" in Patients With Peripheral Arterial Disease (NCT03861416) | POLYSAN Scientific & Technological Pharmaceutical Company | 2018-03-16 |